Announcements

Clinuvel's company releases, including archives.

Clinuvel Newsletter - April 2014

14 Apr 2014

Lapse and Forfeit of Unlisted Conditional Performance Rights

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) wishes to advise in accordance with the terms and conditions of issue that the following unquoted conditional performance rights have lapsed and forfeited. Class Number Exercise Price CUVAK Conditional Performance Rights subject to various performance milestones 62,134 $Nil Consequently, there are now 1,466,482 unlisted conditional performance rights on issue. - End - For more information contact:Darren KeamyCompany SecretaryClinuvel Pharmaceuticals LimitedT: +61 3 9660 4900E: This email address is being protected from spambots. You need JavaScript enabled to view it.

SCENESSE® data to feature at American Academy of Dermatology

Photoprotection, vitiligo programs will be presented to world’s largest dermatology congress Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that data from its global clinical trials of SCENESSE® (afamelanotide 16mg) will be presented this week across the American Academy of Dermatology (AAD) Meeting and two specialist dermatology meetings in Denver, Colorado. American Academy of Dermatology (AAD)Colorado Convention CentreHeld across five days, March 21-25, the AAD is the world’s largest dermatology congress, attracting over 19,400 delegates. Results from the CUV102 study of SCENESSE® in vitiligo, including long-term follow up data and published clinical observations, will be presented across…

Appendix 4D - Half Yearly Report

26 Feb 2014

Phase II study of SCENESSE® in rare skin disorder Hailey-Hailey Disease commences

Physician-led Phase II study commences in Rome Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that a physician-led Phase II study of SCENESSE® (afamelanotide 16mg implant) in patients with the rare Hailey-Hailey Disease (HHD) has commenced in Italy. This study will enrol ten HHD patients to be treated with twelve doses of SCENESSE® during one year, with a three month clinical follow up period. Recruitment of all patients is expected to complete by March 2014. SCENESSE® in HHD In 2012, the first proof of concept open-label pilot study of afamelanotide in HHD was carried out in two…

Appendix 4C (Q2 2013-2014)

31 Jan 2014

EMA’s review of SCENESSE® extended to mid-2014

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that the European Medicines Agency has extended the marketing authorisation application (MAA) review period for its drug SCENESSE® (afamelanotide 16mg implant) to mid-2014. Clinuvel’s MAA for SCENESSE® is aimed at a preventative treatment of the orphan (rare) light-intolerance disorder, erythropoietic protoporphyria (EPP) in adult patients. Clinuvel filed the MAA with the Agency in February 2012. “The review of a first-in-class drug, albeit for an untested disease in which light exposure plays a dominant role, was always going to be subject of a lengthy regulatory review,” Clinuvel’s acting Chief Scientific…

Clinuvel Newsletter - February 2014

Over the past eight years we have emphasised the importance of academic interaction with, and discussion of, Clinuvel’s clinical data internationally. It takes extensive preparation to be able to participate in global conferences which are directly relevant to our research. Topics of academic attention are: dermatogenetics, pigmentation, photodermatology and innovative therapies in dermatology and beyond.

Letter to shareholders, January 2014

  Dear shareholders & friends of Clinuvel, On behalf of the Clinuvel Board and our team I wish all of you a healthy and fortunate 2014. With much excitement our teams and all who are interested in Clinuvel are awaiting the outcome of the European Medicines Agency’s (EMA’s) review of SCENESSE® (afamelanotide 16mg implant) for erythropoietic protoporphyria (EPP) in this coming year. This process has taken longer than any of us could have anticipated, however we welcome the Agency’s tenacity to ensure the drug is given proper evaluation and patients and physicians are given the opportunity to be heard. The…

Lapse and Forfeit of Unlisted Share Options

19 Nov 2013
Page 1 of 32

Investors' Blog Posts

In 2010, Clinuvel announced that it would commence a clinical trial of a new drug for vitiligo. In late 2012 the first treatment results...

Read More

Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...

Read More

Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...

Read More

Related Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Investor Spotlight